Why did Shihe Gene terminate its listing?

Because the service organization was investigated by the CSRC. Shihe Gene is a national high-tech enterprise. According to relevant data, Stone and Gene submitted a prospectus to the Science and Technology Innovation Board two years after Firestone Medicine and Fanzi landed on Nasdaq, but the road to the capital market for the first time was not smooth. Two months after submitting the prospectus, Shihe Gene was investigated by the Securities and Futures Commission on July 29th, and the listing process was suspended.